If those are the requirements for inclusion and eIND, then placebo has the same restrictions... Would think it would result in more deaths in placebo. If anything I'd say it's ensuring that we're looking for effecacy in the extreme / critical. 3 doses would be nice, but benefit should still be seen with 2, considering.